Aeterna Zentaris complete recruitment for 2nd Cetrorelix BPH trial

Æterna Zentaris have completed patient recruitment its second Phase III efficacy trial of cetrorelic in benign prostatic hyperplasia (BPH)

Almirall receive $15M milestone from Forest for aclidinium bromide

Almirall has received a 15 million dollar payment from Forest Laboratories in connection with its phase III development of aclidinium bromide, an antimuscarinic for the treatment of COPD (Chronic Obstructive Pulmonary Disease).

Titan announces positive Phase III results for probuphine in Opioid addiction

Titan Pharmaceuticals have announced positive, statistically significant results from its phase III clinical trial of Probuphine in the treatment of opioid addiction.

CTP extends duration of action of FSH in Phase III trial

Schering-Plough has successfully completed a Phase III trial of its long-acting fertility hormone corifollitropin alfa (FSH-CTP). The duration of action is expanded by the addition of CTP from Modigene.

MAP Pharmas 5-HT1D agonist enter Phase III for migraine

MAP Pharmaceuticals has initiated its first Phase 3 trial of MAP0004 its 5-HT1D agonist for the treatment of Migraine

Scherings FSH Corifollitropin alpha meets primary endpoints

Phase III data presented at the European Society of Human Reproduction and Embryology meeting show Schering-Plough’s FSH analog corifollitropin alpha to have met its primary endpoints

Sciele complete Phase III trial of Glycopyrrolate for Moderate-to-Severe Drooling

Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients

SkyePharmas Third Flutiform Phase III Study meets endpoints

SkyePharma have announced that its third Phase III trial of Flutiform in asthma patients has met its primary endpoints.

Almirall and Forest complete Phase III trials of Aclidinium in COPD

Almirall and Forest have announced that Phase III trials of Aclidinium in COPD are now complete

Mercks CGRP receptor antagonist telcagepant shows efficacy in migraine

Data from a Phase III trial show that Merck’s calcitonin gene-related peptide (CGRP) Receptor antagonist telcagepant (MK-0974) demonstrates migraine relief and has fewer adverse events than Zolmitriptan.